Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.
about
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationHIV-1 subtype B protease and reverse transcriptase amino acid covariationDistinguishing functional amino acid covariation from background linkage disequilibrium in HIV protease and reverse transcriptaseN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityA Rough Set-Based Model of HIV-1 Reverse Transcriptase ResistomeData-intensive analysis of HIV mutations.Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics.High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsTransmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutationsImpact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTColinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencingPanel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceReverse transcriptase inhibitors as potential colorectal microbicides.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.Active site binding and sequence requirements for inhibition of HIV-1 reverse transcriptase by the RT1 family of single-stranded DNA aptamers.Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational PatternIdentification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityMolecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
P2860
Q24792432-DDC1CE0F-6B02-4C22-BFC3-074139EF41D3Q28469203-B00909AD-340A-4DCA-8D70-90E2888D3C71Q28469282-B75429C9-6D3E-4DB6-9F81-9FE5D9DB4E86Q28471689-634FEBCE-843D-4912-A7C5-511D3A7E0502Q28533996-69D96B56-D90E-47A8-A335-2397A767EB06Q30492811-B779106A-6E49-44DF-9450-1CFEEF9FDE1FQ30887525-F69896C4-EEBE-40F8-9A16-DF0BFD43CDF5Q33603586-E619CA25-F4D0-4CDC-96BC-ABEBD0313CD2Q33624190-85D4E178-18FA-44F6-B426-E007C5084813Q33687232-D8095B63-DF0F-4025-839A-0B135284C292Q33911980-12A31EEB-8253-4C8C-824B-ED900F42D17EQ34091371-6B125ADB-4276-4F6E-BEC7-EB7AF84F0E8AQ34717615-4D25798A-BB62-459A-91FA-AFD7FEF642E1Q35122204-F6EE6CA0-C182-41FA-ACAA-C717C1B52C62Q35140450-AE5D7F15-8FBC-4A4F-B09D-FA4949A03F5DQ35676056-BAD00257-4DB1-4989-91CD-BB7C56801D88Q35867047-F5B6A5F8-32D0-4C6F-B8E0-C8E84A81F727Q36099251-4CC8D4F1-2170-4B05-A434-6C2F4D62AA05Q36292765-CFC28997-9BE1-4A24-8D0E-766503748570Q36315090-73769A61-9CBA-4D94-94B0-801FE43A26B5Q36900004-DD9786FD-7A20-49C5-AAAB-6E7A901A39AEQ36900010-92137FA8-28BA-48BC-9DDB-AF16A8154E85Q36950126-F31DD321-99F5-4E3F-A841-A8A9A5130A0FQ36950131-59CF01DC-B582-4797-BC96-A20EA225EF17Q37003252-6E2E0D54-3F6A-4EE5-8C7F-04A513813AEDQ37190754-E7956014-2305-4710-BEDD-58169DE88F79Q37256719-0A450B13-6368-440A-A378-9F007ACCDDFDQ37268341-82E5F0A4-58C5-4E5A-B6FC-A3ED1E7A75D7Q37550353-D28AAA45-C93B-458D-8D44-F368FDDA98BCQ38299800-9A3C5610-9510-402E-A5AF-1BE3763A1442Q39627546-3EA3C8D4-F278-4C71-B50C-4D6AD999C613Q40013658-7AE0FC8F-5EE4-44BF-8F07-697FA1624AE5Q40902737-D6A5F835-D67F-4586-A53D-ADB01BA8BB35Q41495257-5C2A2E7A-D234-4A42-8524-01BD924366BAQ42151695-BC7B130A-EDB6-4A3B-9EDC-48BD621E1BB6Q42209925-34B0FD20-B7C3-4688-AB18-4F8FA59E3F14Q42430831-DBAA7A7E-D1DD-4EDE-9E79-5FFF03CE2231
P2860
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@en
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@nl
type
label
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@en
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@nl
prefLabel
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@en
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@nl
P2093
P2860
P1433
P1476
Extended spectrum of HIV-1 rev ...... nucleoside analog inhibitors.
@en
P2093
Andrew R Zolopa
Dennis Israelski
Ilana Belitskaya
Jonathan Taylor
Matthew J Gonzales
Rami Kantor
Robert W Shafer
Sunwen Chou
Thomas D Wu
W Jeffrey Fessel
P2860
P304
P356
10.1097/00002030-200304110-00003
P407
P577
2003-04-01T00:00:00Z